4D Pharma plc, of Leeds, U.K., reported preclinical data on its single-strain live biotherapeutic candidates, MRx-0005 and MRx-0029, at the Neuro4D conference in Frankfurt, Germany. In a Parkinson's disease model, MRx-0005 had reduced neuroinflammation and MRx-0029 protected against the loss of dopaminergic neurons.